Research Article
The Effect of Gefitinib on Treatment Necessity and Prognosis of NSCLC Patients with Early EGFR Mutations
Table 4
Means and medians of survival analysis times.
| | Take your medication | Average valuea | Median | | Estimate | Standard error | 95% confidence interval | Estimate | Standard error | 95% confidence interval | | Lower limit | Upper limit | Lower limit | Upper limit |
| | Not taking medication | 43.900 | 3.886 | 36.283 | 51.517 | 46.100 | 5.209 | 35.890 | 56.310 | | Take medication | 61.951 | 2.340 | 57.365 | 66.538 | — | — | — | — | | Control group | 54.836 | 2.756 | 49.435 | 60.238 | — | — | — | — | | Overall | 52.961 | 2.027 | 48.988 | 56.934 | 60.700 | — | — | — |
|
|
aIf the survival analysis time has been checked, then the estimate will be limited to the maximum survival analysis time.
|
